A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

NCT07525206 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Telisotuzumab adizutecan
DRUG: Bevacizumab
DRUG: Trifluridine/Tipiracil

Sponsor

AbbVie